FDA approval of QUVIVIQ (daridorexant) for the treatment of insomnia

Idorsia Ltd has announced the FDA approval of QUVIVIQ™ (daridorexant) 25 mg and 50 mg for the treatment of adult patients with insomnia. Insomnia, a serious medical condition, is the most common sleep disorder in the US.

The FDA has recommended that QUVIVIQ be classified as a controlled substance. It is anticipated to be available to patients in May 2022, following scheduling by the US Drug Enforcement Administration.

read more